Please Wait.....
Report
North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market
Market Report I 2023-10-01 I 146 Pages I Data Bridge Market Research
The North America acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 4,096,703.49 thousand by 2030, from USD 1,807,544.80 thousand in 2022, growing at the CAGR of 11.2% in the forecast period of 2023 to 2030.
Market Segmentation
North America Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030
Overview of North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
- Increasing prevalence and incidence of acute lung injury in the market
Restraint
- High cost of device and treatment
Opportunity
- Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the North America Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below:
- Gilead Sciences, Inc.
- Terumo Medical Corporation
- Getinge .
- LivaNova PLC
- Medtronic
- ResMed
- Fisher & Paykel Healthcare Limited.
- Dragerwerk AG & Co. KGaA
- NIPRO
- Fresenius SE & Co. KGaA
- Hamilton Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- EUROSETS
- Armstrong Medical
- nice Neotech Medical Systems Pvt. Ltd.
- Besmed Health Business Corp.
TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 PESTEL ANALYSIS 36
4.2 PORTER'S FIVE FORCES 37
4.3 INSURANCE REIMBURSEMENT 38
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 38
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 38
4.3.3 ABBOTT CODING GUIDE FOR ECMO 39
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 39
4.3.5 CERN HEALTH INSURANCE SCHEME 40
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 40
4.3.7 AMERICAN HOSPITAL ASSOCIATION 41
4.4 PIPELINE ANALYSIS 42
4.5 PRICING ANALYSIS 44
5 MARKET OVERVIEW 45
5.1 DRIVERS 47
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 47
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 47
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 48
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 48
5.2 RESTRAINTS 49
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 49
5.2.2 HIGH COST OF DEVICES AND TREATMENT 49
5.3 OPPORTUNITIES 50
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 50
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 50
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 51
5.4 CHALLENGES 52
5.4.1 STRINGENT RULES & REGULATIONS 52
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 53
6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 54
6.1 OVERVIEW 55
6.2 MECHANICAL VENTILATION 58
6.2.1 HIGH-FLOW NASAL O2 59
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 59
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 59
6.2.4 PRONE POSITION VENTILATION 59
6.2.5 OTHERS 60
6.3 CORTICOSTEROIDS 60
6.3.1 METHYLPREDNISOLONE 61
6.3.2 DEXAMETHASONE 61
6.3.3 OTHERS 61
6.4 ANTIVIRAL MEDICATION 62
6.4.1 RIBAVIRIN 63
6.4.2 OSELTAMIVIR 63
6.4.3 OTHERS 63
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 63
6.6 TOCILIZUMAB 64
6.7 OTHERS 64
?
7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 65
7.1 OVERVIEW 66
7.2 SEPSIS 69
7.3 INHALATION OF HARMFUL SUBSTANCES 69
7.4 SEVERE PNEUMONIA 70
7.5 OTHERS 70
8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 71
8.1 OVERVIEW 72
8.2 PARENTERAL 75
8.2.1 INTRAVENOUS 75
8.2.2 INTRAMUSCULAR 75
8.3 ORAL 76
8.4 OTHERS 76
9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 77
9.1 OVERVIEW 78
9.2 HOSPITALS 81
9.3 SPECIALTY CLINICS 81
9.4 HOME HEALTHCARE 82
9.5 OTHERS 82
10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 83
10.1 OVERVIEW 84
10.2 DIRECT TENDER 87
10.3 HOSPITAL PHARMACY 87
10.4 RETAIL PHARMACY 88
10.5 ONLINE PHARMACY 88
11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 89
11.1 NORTH AMERICA 91
11.1.1 U.S. 96
11.1.2 CANADA 101
11.1.3 MEXICO 106
12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 111
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111
13 SWOT ANALYSIS 112
14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 113
14.1 GILEAD SCIENCES INC. 113
14.1.1 COMPANY SNAPSHOT 113
14.1.2 REVENUE ANALYSIS 114
14.1.3 COMPANY SHARE ANALYSIS 114
14.1.4 PRODUCT PORTFOLIO 115
14.1.5 RECENT DEVELOPMENT 115
14.2 TERUMO CORPORATION 116
14.2.1 COMPANY SNAPSHOT 116
14.2.2 REVENUE ANALYSIS 116
14.2.3 COMPANY SHARE ANALYSIS 117
14.2.4 PRODUCT PORTFOLIO 117
14.2.5 RECENT DEVELOPMENT 117
14.3 GETINGE 118
14.3.1 COMPANY SNAPSHOT 118
14.3.2 REVENUE ANALYSIS 118
14.3.3 COMPANY SHARE ANALYSIS 119
14.3.4 PRODUCT PORTFOLIO 119
14.3.5 RECENT DEVELOPMENT 119
14.4 LIVANOVA PLC 120
14.4.1 COMPANY SNAPSHOT 120
14.4.2 REVENUE ANALYSIS 120
14.4.3 COMPANY SHARE ANALYSIS 121
14.4.4 PRODUCT PORTFOLIO 121
14.4.5 RECENT DEVELOPMENTS 121
14.5 MEDTRONIC 122
14.5.1 COMPANY SNAPSHOT 122
14.5.2 REVENUE ANALYSIS 122
14.5.3 COMPANY SHARE ANALYSIS 123
14.5.4 PRODUCT PORTFOLIO 123
14.5.5 RECENT DEVELOPMENTS 123
?
14.6 ARMSTRONG MEDICAL 124
14.6.1 COMPANY SNAPSHOT 124
14.6.2 PRODUCT PORTFOLIO 124
14.6.3 RECENT DEVELOPMENT 124
14.7 BESMED HEALTH BUSINESS CORP. 125
14.7.1 COMPANY SNAPSHOT 125
14.7.2 PRODUCT PORTFOLIO 125
14.7.3 RECENT DEVELOPMENTS 126
14.8 DRAGERWERK AG & CO. KGAA 127
14.8.1 COMPANY SNAPSHOT 127
14.8.2 REVENUE ANALYSIS 127
14.8.3 PRODUCT PORTFOLIO 128
14.8.4 RECENT DEVELOPMENTS 128
14.9 EUROSETS 129
14.9.1 COMPANY SNAPSHOT 129
14.9.2 PRODUCT PORTFOLIO 129
14.9.3 RECENT DEVELOPMENT 129
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 130
14.10.1 COMPANY SNAPSHOT 130
14.10.2 REVENUE ANALYSIS 130
14.10.3 PRODUCT PORTFOLIO 131
14.10.4 RECENT DEVELOPMENTS 131
14.11 FRESENIUS SE & CO. KGAA. 132
14.11.1 COMPANY SNAPSHOT 132
14.11.2 REVENUE ANALYSIS 132
14.11.3 PRODUCT PORTFOLIO 133
14.11.4 RECENT DEVELOPMENT 133
14.12 HAMILTON MEDICAL 134
14.12.1 COMPANY SNAPSHOT 134
14.12.2 PRODUCT PORTFOLIO 134
14.12.3 RECENT DEVELOPMENT 134
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 135
14.13.1 COMPANY SNAPSHOT 135
14.13.2 PRODUCT PORTFOLIO 135
14.13.3 RECENT DEVELOPMENT 135
14.14 NIPRO 136
14.14.1 COMPANY SNAPSHOT 136
14.14.2 REVENUE ANALYSIS 136
14.14.3 PRODUCT PORTFOLIO 137
14.14.4 RECENT DEVELOPMENT 137
14.15 PFIZER INC. 138
14.15.1 COMPANY SNAPSHOT 138
14.15.2 REVENUE ANALYSIS 138
14.15.3 PRODUCT PORTFOLIO 139
14.15.4 RECENT DEVELOPMENT 139
14.16 RESMED 140
14.16.1 COMPANY SNAPSHOT 140
14.16.2 REVENUE ANALYSIS 140
14.16.3 PRODUCT PORTFOLIO 141
14.16.4 RECENT DEVELOPMENT 141
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 142
14.17.1 COMPANY SNAPSHOT 142
14.17.2 PRODUCT PORTFOLIO 142
14.17.3 RECENT DEVELOPMENT 142
15 QUESTIONNAIRE 143
16 RELATED REPORTS 146
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security